This article in Ottawa Business Journal provides some background on Replica Analytics as an Ottawa start-up leveraging artificial intelligence to revolutionize data sharing in medical trials. Replica Analytics uses machine learning to create synthetic data, mirroring real datasets without compromising patient privacy. Partnering with industry giants like Merck and the University of Alberta, the firm targets life sciences and pharmaceutical research. Market traction is evident, with predictions that soon 60% of data for AI and analytics will soon be synthetically generated. Synthetic data is a game-changing innovation, with the potential to reduce costs and expediting drug development.